CEMES-CNRS, Université de Toulouse, CNRS, 29 rue Jeanne Marvig BP 94347, 31055 Toulouse cedex 4, France; I2MC, Université de Toulouse, INSERM, Hôpitaux de Toulouse, 1 avenue du Professeur Jean PoulhèsBP 8422531432 Toulouse Cedex 4, France.
CHROMALYS SAS, 29 rue Jeanne Marvig, 31400 Toulouse, France.
Acta Biomater. 2020 May;108:261-272. doi: 10.1016/j.actbio.2020.03.013. Epub 2020 Mar 9.
For some years now, gadolinium oxysulfide nanoparticles (NPs) appear as strong candidates for very efficient multimodal in vivo imaging by: 1) Magnetic Resonance (MRI), 2) X-ray Computed Tomography (CT) and 3) photoluminescence imaging. In this paper, we present a selection of results centered on the evaluation of physico-chemical stability, toxicity, bio-distribution and excretion mechanisms of GdOS:Ln nanoparticles intravenously injected in rats. Two formulations are here tested with a common matrix and different dopants: GdOS:Eu and GdOS:Yb/Tm. The NPs appear to be almost insoluble in pure water and human plasma but corrosion/degradation phenomenon appears in acidic conditions classically encountered in cell lysosomes. Whole body in vivo distribution, excretion and toxicity evaluation revealed a high tolerance of nanoparticles with a long-lasting imaging signal associated with a slow hepatobiliary clearance and very weak urinary excretion. The results show that the majority of the injected product (>60%) has been excreted through the feces after five months. Experiments have evidenced that the NPs mainly accumulate in macrophage-rich organs, that is mainly liver and spleen and to a lesser extent lungs and bones (mainly marrow). No significant amounts have been detected in other organs such as heart, kidneys, brain, intestine and skin. GdOS:Ln NPs appeared to be very well tolerated up to 400 mg/kg when administered intravenously. STATEMENT OF SIGNIFICANCE: Since 2011, we have focused our work on GdOS nanoparticles (NPs) for multimodal bioimaging using fluorescence, Magnetic Resonance Imaging (MRI) and Computed Tomography with very efficient results already published. However, since the European Medicines Agency has concluded its review of gadolinium contrast agents, confirming recommendations to restrict the use of some linear gadolinium agents used in MRI, a particular attention must be paid to any new contrast media containing gadolinium. Therefore, we present in this paper a compilation of studies about toxicity, bio-distribution and excretion mechanisms of GdOS:Ln NPs intravenously injected into rats. We also present an in vitro kinetic study of NPs degradation in aqueous and biological media to provide some information on chemical and biological stability.
几年来,硫化钆纳米粒子(NPs)因其在以下方面的应用而成为非常高效的多模态体内成像的有力候选者:1)磁共振(MRI),2)X 射线计算机断层扫描(CT)和 3)荧光成像。在本文中,我们介绍了一系列围绕静脉注射入大鼠的 GdOS:Ln 纳米粒子的物理化学稳定性、毒性、生物分布和排泄机制的评估结果。本文中测试了两种制剂,它们具有共同的基质和不同的掺杂剂:GdOS:Eu 和 GdOS:Yb/Tm。这些 NPs 在纯水中几乎不溶解,在人血浆中也几乎不溶解,但在细胞溶酶体中常见的酸性条件下会发生腐蚀/降解现象。全身体内分布、排泄和毒性评估显示,纳米粒子具有很高的耐受性,具有与之相关的长时间成像信号,且具有缓慢的肝胆清除和非常弱的尿液排泄。结果表明,超过 60%的注射产品在五个月后通过粪便排出体外。实验表明,纳米粒子主要在富含巨噬细胞的器官中积累,即主要在肝脏和脾脏中,在较小程度上在肺和骨骼(主要是骨髓)中积累。在其他器官(如心脏、肾脏、大脑、肠道和皮肤)中未检测到大量的 NPs。当静脉内给予 400mg/kg 时,GdOS:Ln NPs 表现出非常好的耐受性。意义声明:自 2011 年以来,我们一直专注于使用荧光、磁共振成像(MRI)和计算机断层扫描的 GdOS 纳米粒子(NPs)进行多模态生物成像,已经发表了非常有效的结果。然而,由于欧洲药品管理局已经完成了对钆造影剂的审查,确认了限制在 MRI 中使用某些线性钆造影剂的建议,因此必须特别注意任何含有钆的新造影剂。因此,本文介绍了静脉注射入大鼠的 GdOS:Ln NPs 的毒性、生物分布和排泄机制的研究综述。我们还介绍了 NPs 在水相和生物介质中的降解的体外动力学研究,以提供有关化学和生物稳定性的一些信息。